Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: inside layer (24), coating (68), liner (5)

Pembrolizumab_200mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (200mg) Regimen • Lymphoma – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-200mg.pdf

Nivolumab (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab Regimen • Lymphoma – Nivolumab Indication • Nivolumab is recommended as an option for treating relapsed or refractory classical Hodgkin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab.pdf

Nivolumab 240mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab (240mg-14 days) Regimen • Lymphoma – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab-240mg.pdf

InP-REPOCH-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine

Description: Chemotherapy Protocol LYMPHOMA REPOCH - CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONERITUXIMAB-VINCRISTINE (In-Patient Dose adjusted regimen) There are multiple versions of this protocol
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-REPOCH.pdf

Audit and Risk Committee ToR Jan 2022

Description: Audit and Risk Committee Terms of Reference Date Issued: 27 January 2022 Review Date: January 2023 Document Type: Committee Terms of
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2022.pdf

MyelomaVCD(SC28)Bortezomib(SC)CyclophosphamideDexamethasone28dayVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-28) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (28 day) Regimen Multiple Myeloma – VCD (SC-28)-Bortezomib (SC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVCDSC28BortezomibSCCyclophosphamideDexamethasone28dayVer1.pdf

MyelomaVCD(SC21)Bortezomib(SC)CyclophosphamideDexamethasone21dayVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-21) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (21 day) Regimen Multiple Myeloma – VCD (SC-21)-Bortezomib (SC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVCDSC21BortezomibSCCyclophosphamideDexamethasone21dayVer1.pdf

MyelomaVCD(IV28)Bortezomib(IV)CyclophosphamideDexamethasone28dayVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-28) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (28 day) Regimen Multiple Myeloma – VCD (IV-28)-Bortezomib (IV
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVCDIV28BortezomibIVCyclophosphamideDexamethasone28dayVer1.pdf

Myeloma VCD (SC35) bortezomib (SC) cyclophosphamide dexamethasone 35 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-35) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Myeloma – VCD (SC-35)-Bortezomib (SC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-SC35-bortezomib-SC-cyclophosphamide-dexamethasone-35-day.pdf

Myeloma VCD (IV35) bortezomib (IV) cyclophosphamide dexamethasone 35 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-35) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Myeloma – VCD (IV-35)-Bortezomib (IV
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-IV35-bortezomib-IV-cyclophosphamide-dexamethasone-35-day.pdf

701 to 710 of 748

Previous … 69 70 71 72 73 … Next